Study S000809

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07509112
Acronym: SHIFT
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 40
Start: 2026-09
Primary completion: 2027-01
Lead sponsor: Kirby Institute
Conditions: Methamphetamine Use Disorder
Interventions: DRUG:12 weeks of weekly subcutaneous semaglutide injection
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Efficacy Outcome (exploratory) [12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.